Tagged: biotech

State of Private Markets Report from Carta: Astonishing New High in Rounds, Funds Raised in Past Year

In order to assist investors, company founders, and workers with making informed decisions and benchmark past performance, Carta has shared key insights from their private market data. Carta points out in an extensive report that this past year saw an “astonishing new high in rounds… Read More

Top Tech Sector Investments to Soar in Next 5 Years

While recent levels of investment in the most attractive tech sectors are impressive, you ain’t seen nothing yet. According to market reports nanotechnology, AI, digital twins, genomics, and other biotech life sciences, which attracted $893 billion of investment last year, will draw $2.44 trillion by… Read More

U.S. Fintech Brex Teams Up With Science Exchange to Offer Biotech Incentives

Science Exchange, a technology platform that is used by research organizations to order and manage outsourced R&D services, announced a strategic partnership with U.S. fintech, Brex. According to Science Exchange, the new partnership will see Brex offer biotech incentives. While sharing more details about the… Read More

Phoenix PharmaLabs Celebrates Successful Netcapital Equity Offering for Non-Addictive Opioid Pain Treatment

Phoenix PharmaLabs, Inc., a private company developing what is reportedly the world’s first non-addictive opioid for treatment of moderate to severe pain, recently celebrated a successful equity offering of more than $1.1 million via Netcapital, an SEC-approved equity funding portal. A combination of accredited and… Read More

20/20 Gene Systems Biotech SeedInvest/Crowdcube Campaign Now 1090%+ Overfunding

Machine learning, algorithms, early cancer detection, successful intervention? 20/20 GeneSystems, a digital diagnostics company with the core mission of reducing cancer mortality in the U.S. and around the world through early detection, sells what it believes to be the first multi-cancer blood test powered by real-world… Read More

Airmony Sleep Apnea Device Co. Nears Crowdfunding Goal Early in Crowdcube Campaign: Sweet Dreams

Airmony, a new portable, light and tubeless sleep apnea e-tech device, pushes a continuous flow of air to help sleep apnea patients breathe and enjoy a good night’s sleep. The Barcelona-based company synced with Crowdcube to raise £200,000 and has surpassed £146,100 in the first three days… Read More

Arcis Biotechnology Crowdfunds on Capital Cell, Seeks £1.75 Million

Arcis Biotechnology is crowdfunding on Capital Cell now having already raised £1.25 million. The company is hoping to raise £1.75 million at a pre-money valuation of £18.2 million. Capital Cell “endorses” this company and has posted the following statement: “Arcis’ technology allows the extraction of… Read More

CataloniaBio Member Cebiotex Crowdequity Round Now Live on CapitalCell: Fighting Pediatric Cancer

Cebiotex, a CataloniaBio member, has launched a new crowdequity campaign to raise €650,000 through CapitalCell in order to ensure its first drug, CEB-01 for post-op treatment of soft-tissue sarcomas, reaches pediatric oncology. The campaign is part of a larger €1.6-million round of funding; since launching, the… Read More

Biotecher ImmunoLogik Syncs with aescuvest to Back Anti-HIV Drug, Nears Initial Funding Goal

The ImmunoLogik GmbH and the University of Erlangen-Nuremberg HIV research team have synced with aescuvest to raise funding for an innovative new drug. To date, the biotech company has raised more than €77,940, or more than 75% of its initial €100,000 goal. ImmunoLogik GmbH, a biotechnology company… Read More

Capital Cell Shortlisted for UK Business Angels Association Investment Award

Capital Cell, reportedly Europe’s first equity crowdfunding platform specializing in life science, has been shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017. Capital Cell has been trading in Spain for just over 2 years, successfully closing 14 life… Read More

MoU Signed: Aescuvest Partners with Touwho for Medtech & Biotech Growth

Frankfurt-based company aescuvest, an equity crowdfunding platform specializing in the innovative healthcare market and targeting new areas for growth outside Germany has penned a  deal with new Chinese partner Shenzhen-based Touwho Network & Fund, a medtech and biotech crowdfunding platform, and the Medical Valley European Metropolitan Region Nuremberg. “Startups and entrepreneurs… Read More

23 Healthtech Investments & Counting: OurCrowd Invests $2.5M in Scopio Labs

OurCrowd, a global leader in equity crowdfunding, today announced that it will invest $2.5 million (as part of a recently completed $7 million investment round) in Scopio Labs, a developer of an advanced digital microscopy and diagnostics platform. This is OurCrowd’s 23rd healthtech investment for… Read More

Capital Cell Celebrates Bionure’s Recordbreaking Spanish Biotech Crowdfunding Campaign, Plans UK Launch

Bionure, a Spanish biotech company developing a  first-in-class drug for the treatment of multiple sclerosis, is currently 115% overfunding on Capital Cell. With more than €1,100,246 raised, Bionure has broken the record for the highest amount raised on a Spanish life science equity crowdfunding platform. Valued at… Read More

Cantor Fitzgerald’s Jim Shiggins: Why I Invested in SyndicateRoom’s Hibergene Campaign

Today Hibergene‘s Series B funding round on SyndicateRoom will successfully close at midnight tonight, having raised at least £5,707,336 with the help of over 53 investors. Funds will be used to support R&D activities to launch three new products in 2017. The Irish medical diagnostics company specializes in the urgent diagnosis… Read More

Irish Biotech Hibergene Diagnostics Links with SyndicateRoom for Series B Round

Hibergene Diagnostics has linked with SyndicateRoom for its Series B round alongside key institutional investor, Cantor Fitzgerald. Hibergene, an Irish medical diagnostics company that specialises in the urgent diagnosis of potentially fatal human infectious diseases, has developed what it believes to be a simple, easy to use and low… Read More

BCN Biotech Aromics Nears 100K€ Crowdfunding on Capital Cell

Aromics, a privately-owned development stage pharmaceutical company founded in 2005, is based in Barcelona, Spain and focused on developing novel first-in-class therapies for the treatment of human diseases. The company has received the seal of Innovative SME from MINECO and achieved different R&D awards from international,… Read More

Clínica Dialibre: Spain’s First Diabetes Youth Clinic Quickly Closes in on CapitalCell Crowdfunding Goal

Clínica Dialibre, the first clinic in Spain to specialize in diabetes for children, opened in March 2016 with the mission of setting a milestone in the treatment of diabetes and improving the young patients’ quality of life by personalizing the treatment for each patient. The Clinica… Read More

Igniting a Microbiome Revolution: Era7 Bioinformatics Syncs with Capital Cell

This Capital Cell crowfunding campaign is a unique opportunity to co-invest with an undisclosed VC firm in Era7 Bioinformatics, a Spanish company focused on the revolution of the Microbiome and providing new solutions to address the problem of antibiotic resistance. Era7 Bioinformatics uses its own algorithms… Read More

Biotech NALIA Systems Gain Traction on Syndicate Room with Individual Investor Support

NALIA Systems has created a point-of-care, lab-grade diagnostics array that delivers results in 20 minutes which  gives doctors the in-house tools required to diagnose certain diseases from within their surgery. Although still in prototype mode, a first customer has already been secured. In addition to this potentially disruptive technology, NALIA… Read More

After CNMV Approval, Spain’s Capital Cell Sets Sights on UK Market and FCA Approval

In late July, Barcelona-based Capital Cell received Comisión Nacional del Mercado de Valores (CNMV) approval to operate as a “Participatory Financing Platform.” This authorization includes the capability to select and publish financing projects and also gives Capital Cell the right to operate as an investment… Read More

Send this to a friend